Clinical Trials Browser

Phase 1 × Recurrence × Plasma cell × Clear all

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06425991 2026-03-13

MajesTEC-10

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Phase 1 Recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06215118 2026-02-05

MagnetisMM-30

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07369895 2026-01-27

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-01-26

MagnetisMM-20

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT04398680 2025-12-04

DREAMM 13

Phase 1 Withdrawn

Multiple Myeloma, Recurrence

NCT07003555 2025-11-26

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07003568 2025-11-26

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06381141 2025-09-18

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04756726 2025-09-10

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT05913804 2025-08-15

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Phase 1 Not yet recruiting

LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

NCT05011097 2025-07-20

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT03486067 2025-04-17

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence

NCT04975399 2025-03-24

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence

NCT05227144 2025-03-20

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence

NCT04684108 2025-03-13

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Phase 1 Active not recruiting

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT02245867 2025-02-07

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Phase 1 Completed

Immunoglobulin Light-chain Amyloidosis, Recurrence

NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02043847 2024-11-13

BMT-03

Phase 1 Completed

12 enrolled 12 charts

Multiple Myeloma, Recurrence, Disease Progression

NCT03755154 2024-10-16

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT03710915 2024-10-10

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence

NCT04798586 2024-09-27

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Phase 1 Completed

4 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02099539 2024-09-26

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

19 enrolled 22 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence

NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Phase 1 Terminated

LymphoidPlasma cell

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT04036461 2024-08-30

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence

NCT06500507 2024-07-15

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma, Recurrence

NCT04771572 2024-04-24

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT06084962 2023-10-16

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06082596 2023-10-13

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04613557 2023-08-31

IMMUNICY-1

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05918250 2023-08-18

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1 Withdrawn

Multiple Myeloma, Recurrence

NCT04214093 2023-08-02

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Recurrence, Tumor Lysis Syndrome, Hematologic Neoplasms

NCT05920876 2023-06-27

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Phase 1 Unknown

Multiple Myeloma, Recurrence

NCT04136756 2023-06-15

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Neoplasms, Recurrence

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Unknown

Multiple Myeloma, Recurrence

NCT05007418 2023-01-17

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Phase 1 Unknown

Multiple Myeloma, Recurrence

NCT02468687 2022-05-05

NMP in Relapsed / Refractory Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence